Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Review of new lipid formulations of amphotericin B
Autore:
Andres, E; Tiphine, M; Letscher-Bru, V; Herbrecht, R;
Indirizzi:
Hop Hautepierre, Serv Med Interne & Nutr, F-67098 Strasbourg, France Hop Hautepierre Strasbourg France F-67098 tr, F-67098 Strasbourg, France
Titolo Testata:
REVUE DE MEDECINE INTERNE
fascicolo: 2, volume: 22, anno: 2001,
pagine: 141 - 150
SICI:
0248-8663(200102)22:2<141:RONLFO>2.0.ZU;2-6
Fonte:
ISI
Lingua:
FRE
Soggetto:
INVASIVE FUNGAL-INFECTIONS; MARROW TRANSPLANT RECIPIENTS; CRITICALLY ILL PATIENTS; COLLOIDAL DISPERSION; CRYPTOCOCCAL MENINGITIS; NEUTROPENIC PATIENTS; RANDOMIZED TRIAL; FAT EMULSION; VISCERAL LEISHMANIASIS; ANTIFUNGAL ACTIVITY;
Keywords:
amphotericin B; amphotericin B in fat emulsion; amphotericin B colloidal dispersion; amphotericin B lipid complex; liposomal amphotericin B; invasive fungal infections;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
84
Recensione:
Indirizzi per estratti:
Indirizzo: Andres, E Hop Hautepierre, Serv Med Interne & Nutr, Ave Moliere, F-67098 Strasbourg,France Hop Hautepierre Ave Moliere Strasbourg France F-67098 rg,France
Citazione:
E. Andres et al., "Review of new lipid formulations of amphotericin B", REV MED IN, 22(2), 2001, pp. 141-150

Abstract

Introduction. - Amphotericin B (amB) remains the gold standard for treatment of invasive fungal infections. Lipid formulations of amB have been developed in an attempt to improve both efficacy and tolerability (especially renal toxicity): amB lipid complex (ABLC), liposomal amB (AmBisome(R)), amB colloidal dispersion (ABCD) and amB in lipid emulsion (Intralipid(R)). This review analyzes the data available in the literature. Current knowledge and key points. - ABLC, AmBisome and ABCD are effective in various fungal infections, including invasive aspergillosis, systemic candidiasis, cryptococcal meningitis, mucormycosis and fusariosis. These formulations are also effective in persistent febrile neutropenia and in leishmaniosis The three formulations show little renal toxicity and are safer than conventional amB in this respect. Preliminary data are available on amB in Intralipid: infusion-related adverse effects are reduced, but few data are available on efficacy in documented mycoses. Future prospects and projects. - Large-scale comparative clinical trials may clarify issues of relative efficacy in various forms of fungal infections. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/09/20 alle ore 15:24:16